- Home
- Products
Trodelvy (Sacituzumab Govitecan-hziy)
Trodelvy (Sacituzumab Govitecan-hziy)
- Medicine Name: Trodelvy
- Generic Name: Sacituzumab Govitecan-hziy
- Dosage Form & Strength: For Injection – 180 mg / 200 mg lyophilized powder (single-dose vial)
- Manufactured By: Gilead Sciences, Inc.
Trodelvy is a Trop-2-directed antibody-drug conjugate (ADC) combined with a topoisomerase I inhibitor for the treatment of adult patients with:
- Metastatic Triple-Negative Breast Cancer (mTNBC) who have received ≥2 prior therapies for metastatic disease
- Locally Advanced or Metastatic Urothelial Cancer (mUC) previously treated with platinum-containing chemotherapy and a PD-1/PD-L1 inhibitor
Recommended Dosage:
- 10 mg/kg on Days 1 and 8 of a 21-day cycle
- Continue until disease progression or unacceptable toxicity
- IV infusion only (do not administer as IV push or bolus)
- Pre-infusion medications and close monitoring recommended
evere Neutropenia: Monitor neutrophil counts; withhold for ANC <1500/mm³ (Day 1) or <1000/mm³ (Day 8), or for neutropenic fever
- Severe Diarrhea: Manage with antidiarrheals; withhold treatment if Grade 3–4 diarrhea is present
- Hypersensitivity Reactions: Pre-medicate and monitor closely during and after infusion
- UGT1A1*28 Risk: Homozygous individuals are at higher risk of adverse reactions—monitor closely
- Fetal Harm: May cause fetal toxicity—advise contraception during treatment and for 6 months (females) and 3 months (males) post-treatment
- Breastfeeding: Avoid during and for 1 week after last dose
Required Documents for Import to India:
- Valid prescription from a qualified oncologist
- Diagnostic reports
- Government-issued photo ID
Order Confirmation:
- Confirmed upon submission of all required documentation and applicable import permit
Available In:
Mumbai, Delhi, Chennai, Hyderabad, Bangalore, Kolkata, Pune, Ahmedabad, Lucknow, Noida, Gurgaon, Chandigarh, Jaipur, Ludhiana, and other major Indian cities
Also available for export to: Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Pakistan, Sri Lanka
📞 To Order / Get Pricing:
Call or WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
Global Rare Meds sources Trodelvy from approved global suppliers across USA, Canada, Europe, and Australia, ensuring:
- Verified quality and traceability
- WHO-GDP & ISO-certified dispatch from our fulfillment center in Ambernath, Thane District
- Worldwide shipping with proper handling and legal compliance
What is the generic name of Trodelvy®?
Sacituzumab Govitecan-hziy
FDA Approval Date?
April 22, 2020
What type of medicine is Trodelvy®?
A novel Antibody-Drug Conjugate (ADC) with a targeted delivery system, distinct from traditional chemotherapy
What is Trodelvy® used for?
mTNBC and previously treated advanced urothelial cancer
Common Side Effects?
Nausea, fatigue, diarrhea, neutropenia, vomiting, alopecia, appetite loss, rash, abdominal pain
How is Trodelvy® administered?
IV infusion on Day 1 and Day 8 of every 21-day cycle
Storage Requirements:
Store between 2°C to 8°C (36°F to 46°F); do not freeze
Is hair loss expected with Trodelvy®?
Yes, temporary alopecia is a known side effect in many patients
What is the treatment duration?
Until disease progression or intolerable toxicity. Number of cycles may vary by patient response
Where is Trodelvy® available in Asia?
Available via named-patient import in India, Nepal, Bangladesh, Pakistan, Afghanistan, Bhutan, Maldives, Sri Lanka
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
